Welcome to the recently named
TRIO (Translational Research in Oncology) organization
(ex-Cancer International Research Group).
TRIO is a not-for-profit clinical research organization with offices based in Canada, France and Uruguay.
With an international network of 2000 investigators and 450 cancer centers in over 45 different countries, TRIO has conducted a number of new and innovative global studies evaluating systemic therapy for cancer.
TRIO entity comes from the merge of CIRG and TORI the wide group of preclinical researchers at UCLA to become part of an exciting innovative translational research program.
TRIO is developing from proof of concept up to registrational phase III trials in different setting such as breast, ovary, GI….
> Last News :
The Translational symposium:
"Hot Topics in Translational Research: Transforming
Cutting-Edge Discoveries to Clinical Practice"
proposed and presented by TRIO Directors
held early June at ASCO and organised by CCO (www.clinicaloptions.com/translational2011) in partnership with TRIO, was a great success. By clicking on each items of the agenda below you will be able to access to each presentations graciously provided by each speaker for your reference. Please save first on your computer to allow quick reading!.
Welcome and Introduction
Dennis J. Slamon, MD, PhD Program Chair
Identifying Tumors Expressing Predictive Markers: Lessons Learned From HER2
Dennis J. Slamon, MD, PhD
IGFR: A New Target for Multiple Tumor Types
Gottfried Konecny, MD
Targeting the PI3K Pathway
Carlos L. Arteaga, MD
Antireplication Agents: CDK Inhibitors and Telomerase Inhibitors
Richard Finn, MD
Antiangiogenesis: Using Old and New Approaches
John R. Mackey, MD, FRCP(C)
DNA Repair Pathways and PARP Inhibition
Nicholas Turner, MD
Panel Discussion/Concluding Remarks
For information on new TRIO-CIRG studies please click in the Studies Summary on left side menu.